Recent Updates
Recently added Catalysts
CRVO Positive Sentiment Score: 70/100

CervoMed to Participate in the BIO CEO and Investor Conference

Wednesday, February 21, 2024 1 min read
Key Takeaway: CervoMed Inc. (NASDAQ: CRVO) announced its participation in the upcoming BIO CEO and Investor Conference scheduled for February 26, 2024, in New York City. The company is focused on developing treatments for degenerative brain diseases, particularly through its investigational drug, neflamapimod. This medication is being evaluated for its potential to treat synaptic dysfunction in conditions like dementia with Lewy bodies. CervoMed's management will also engage in one-on-one investor meetings during the conference.

Market Sentiment Analysis

POSITIVE FACTORS

  • CervoMed is actively participating in the BIO CEO and Investor Conference, highlighting its commitment to advancing its research.
  • The company is developing neflamapimod, which has potential therapeutic applications for neurodegenerative diseases.
  • CervoMed's participation suggests investor interest and confidence in its pipeline.

Full Press Release Details

BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company’s Management will present at the BIO CEO and Investor Conference on February 26, 2024, being held in New York, NY and participate in one-on-one investor meetings.
Presentation Details
Format: Corporate presentation
Date: Monday, February 26, 2024
To learn more about the BIO CEO and Investor Conference please visit https://bcic.bio.org/.
CervoMed Inc. is a clinical-stage company focused on developing treatments for degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in dementia with Lewy bodies (DLB) and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.
Investors@cervomed.com

Frequently Asked Questions

What is CervoMed Inc. focused on?

CervoMed Inc. focuses on developing treatments for degenerative brain diseases.

When will CervoMed present at the BIO CEO Conference?

CervoMed will present on February 26, 2024, at the BIO CEO Conference.

What is neflamapimod?

Neflamapimod is an investigational oral small molecule targeting p38MAP kinase alpha.

What is the goal of neflamapimod?

Neflamapimod aims to treat synaptic dysfunction in dementia with Lewy bodies.

What study is CervoMed conducting for neflamapimod?

CervoMed is evaluating neflamapimod in a Phase 2b study for DLB patients.

Tags: CRVO Viatris Investor Conferences Healthcare CervoMed neflamapimod brain diseases investor conference clinical stage
Last updated: Feb 21, 2024